Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Open Access
- 10 September 2026
- journal article
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 307-313
Abstract
Objectives: Tegoprazan is a novel potassium-competitive acid blocker that rapidly suppresses acid secretion. This study aimed to evaluate the efficacy of tegoprazan 50 mg compared with esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms.Methods: This double-blind, randomized, active-control study was conducted to compare the efficacy of tegoprazan 50 mg and esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. The primary endpoint was the percentage of nocturnal heartburn-free days over 2 weeks. The secondary endpoint was the percentage of patients who experienced relief from nocturnal heartburn within 24 h of the first dose. Additionally, the time to the first nocturnal heartburn-free interval was compared between the two groups.Results: Of 160 patients, 149 were included in the final analysis. The percentage of nocturnal heartburn-free days over 2 weeks was not inferior to that with esomeprazole (58.2% vs. 54.5%, p=0.001). The percentage of patients without nocturnal heartburn for 24 h was higher in the tegoprazan group, although the difference was not statistically significant. The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant.Conclusions: Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may provide more rapid relief from nocturnal heartburn symptoms.Keywords
Funding Information
- HK inno.N Corporation
This publication has 22 references indexed in Scilit:
- Sorting out the Relationship between Gastroesophageal Reflux Disease and SleepCurrent Gastroenterology Reports, 2021
- Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux diseaseAlimentary Pharmacology & Therapeutics, 2021
- Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2018
- The Effect of Dexlansoprazole MR on Nocturnal Heartburn and GERD-Related Sleep Disturbances in Patients With Symptomatic GERDAmerican Journal of Gastroenterology, 2011
- Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthroughCochrane Database of Systematic Reviews, 2009
- Addition of a H2 Receptor Antagonist to PPI Improves Acid Control and Decreases Nocturnal Acid BreakthroughJournal of Clinical Gastroenterology, 2008
- Non-Erosive Reflux Disease (NERD) and Erosive Esophagitis - a Spectrum of Disease or Special Entities?Zeitschrift für Gastroenterologie, 2007
- Effectiveness of proton pump inhibitors in nonerosive reflux diseaseClinical Gastroenterology and Hepatology, 2004
- Non‐erosive reflux disease (NERD) — acid reflux and symptom patternsAlimentary Pharmacology & Therapeutics, 2003
- Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitorsAmerican Journal of Gastroenterology, 1998